Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1023

1.

Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer.

Murphy K, Murphy BT, Boyce S, Flynn L, Gilgunn S, O'Rourke CJ, Rooney C, Stöckmann H, Walsh AL, Finn S, O'Kennedy RJ, O'Leary J, Pennington SR, Perry AS, Rudd PM, Saldova R, Sheils O, Shields DC, Watson RW.

Mol Oncol. 2018 Jun 21. doi: 10.1002/1878-0261.12348. [Epub ahead of print]

2.

Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient.

Doll S, Kriegmair MC, Santos A, Wierer M, Coscia F, Neil HM, Porubsky S, Geyer PE, Mund A, Nuhn P, Mann M.

Mol Oncol. 2018 Jun 14. doi: 10.1002/1878-0261.12326. [Epub ahead of print]

3.

Prognostic, predictive and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA.

Mol Oncol. 2018 Jun 14. doi: 10.1002/1878-0261.12347. [Epub ahead of print]

4.

Modulating ATP Binding Cassette (ABC) Transporters in Papillary Renal Cell Carcinoma Type 2 Enhances its Response to Targeted Molecular Therapy.

Saleeb RM, Farag M, Lichner Z, Brimo F, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM.

Mol Oncol. 2018 Jun 13. doi: 10.1002/1878-0261.12346. [Epub ahead of print]

5.

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.

Cheon SK, Kim HP, Park YL, Jang JE, Lim Y, Song SH, Han SW, Kim TY.

Mol Oncol. 2018 Jun 13. doi: 10.1002/1878-0261.12345. [Epub ahead of print]

6.

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M.

Mol Oncol. 2018 Jun 9. doi: 10.1002/1878-0261.12332. [Epub ahead of print]

7.

CPP-E1A fusion peptides inhibit CtBP-mediated transcriptional repression.

Blevins MA, Zhang C, Zhang L, Li H, Li X, Norris DA, Huang M, Zhao R.

Mol Oncol. 2018 Jun 7. doi: 10.1002/1878-0261.12330. [Epub ahead of print]

8.

Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4+ Treg in Non-Human Primates.

Wang Z, Louras NJ, Lellouch AG, Pratts SG, Zhang H, Wang H, Huang CA, Cetrulo CL Jr, Madsen JC, Sachs DH, Wang Z.

Mol Oncol. 2018 Jun 5. doi: 10.1002/1878-0261.12331. [Epub ahead of print]

9.
10.

miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation.

Hoey C, Ray J, Jeon J, Huang X, Taeb S, Ylanko J, Andrews DW, Boutros PC, Liu SK.

Mol Oncol. 2018 May 30. doi: 10.1002/1878-0261.12328. [Epub ahead of print]

11.

Loss of Androgen Receptor Signaling in Prostate Cancer-Associated Fibroblasts (CAFs) Promotes CCL2 and CXCL8 Mediated Cancer Cell Migration.

Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, Wessels LF, Zwart W, Bergman AM.

Mol Oncol. 2018 May 28. doi: 10.1002/1878-0261.12327. [Epub ahead of print]

12.

A combined tissue-engineered/in silico signature tool patient stratification in lung cancer.

Göttlich C, Kunz M, Zapp C, Nietzer SL, Walles H, Dandekar T, Dandekar G.

Mol Oncol. 2018 May 24. doi: 10.1002/1878-0261.12323. [Epub ahead of print]

13.

Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism.

Cho YR, Lee JH, Kim JH, Lee SY, Yoo S, Jung MK, Kim SJ, Yoo HJ, Pack CG, Rho JK, Son J.

Mol Oncol. 2018 May 23. doi: 10.1002/1878-0261.12324. [Epub ahead of print]

14.

Molecular subtype classification of urothelial carcinoma in Lynch syndrome.

Therkildsen C, Eriksson P, Höglund M, Jönsson M, Sjödahl G, Nilbert M, Liedberg F.

Mol Oncol. 2018 May 23. doi: 10.1002/1878-0261.12325. [Epub ahead of print]

15.

Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma.

Mikheev AM, Mikheeva SA, Severs LJ, Funk CC, Huang L, McFaline-Figueroa JL, Schwensen J, Trapnell C, Price ND, Wong S, Rostomily RC.

Mol Oncol. 2018 May 13. doi: 10.1002/1878-0261.12320. [Epub ahead of print]

16.

Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4.

Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL; Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM.

Mol Oncol. 2018 May 9. doi: 10.1002/1878-0261.12319. [Epub ahead of print]

17.

Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells.

Teslow EA, Bao B, Dyson G, Legendre C, Mitrea C, Sakr W, Carpten JD, Powell I, Bollig-Fischer A.

Mol Oncol. 2018 May 9. doi: 10.1002/1878-0261.12316. [Epub ahead of print]

18.

GRP78-mediated antioxidant response and ABC transporter activity confers chemoresistance to pancreatic cancer cells.

Dauer P, Sharma NS, Gupta VK, Nomura A, Dudeja V, Saluja A, Banerjee S.

Mol Oncol. 2018 May 8. doi: 10.1002/1878-0261.12322. [Epub ahead of print]

19.

Genotoxic stress induces Sca-1-expressing metastatic mammary cancer cells.

Gong J, Lang BJ, Weng D, Eguchi T, Murshid A, Borges TJ, Doshi S, Song B, Stevenson MA, Calderwood SK.

Mol Oncol. 2018 May 8. doi: 10.1002/1878-0261.12321. [Epub ahead of print]

20.

Genomewide binding of transcription factor Snail1 in triple-negative breast cancer cells.

Maturi V, Morén A, Enroth S, Heldin CH, Moustakas A.

Mol Oncol. 2018 May 4. doi: 10.1002/1878-0261.12317. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center